Back to News
Market Impact: 0.35
Pulnovo Medical gibt Ergebnisse der PADN-HF-PH-Studie auf dem ESC-Kongress 2026 bekannt; diese werden gleichzeitig im „New England Journal of Medicine" (NEJM) veröffentlicht
Source: PR Newswire
Healthcare & BiotechCompany FundamentalsTechnology & Innovation
Klinische Ergebnisse bei 264 PH-LHD-Patientinnen und -Patienten zeigen eine 51%ige Risikoreduktion für klinische Verschlechterungen. Zusätzlich sank die Rate wiederkehrender klinischer Ereignisse um 35,5%. Das deutet auf einen klaren therapeutischen Nutzen der untersuchten Behandlung hin.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
More News
- AI rapidly improving, could vastly boost U.S. GDP, Anthropic's Clark tells policymakers
- ‘How many canaries have we killed in the coal mine?’ — Wall Street debates if the latest AI bubble warnings are another head fake or the real thing
- Semiconductor market to remain solid ‘at least through next year,’ South Korea finance minister says
- Nasdaq Index: AI Selloff Deepens as Chips and CoreWeave Break
- Bending Spoons wants to revive software castoffs. Berkshire is backing the plan
- Alphabet’s chief investment officer responds to Jefferies warning that the most likely outcome of the AI boom is massive U.S. capital destruction
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Index and ETF Holdings Data for AI Research
- Capital Intensity as Gravity: The AI Trade Enters Its Industrial Era (Looking at Q3 2025 Earnings in Tech)